Related by context. Frequent words. (Click for all words.) 80 Patient Enrollment 77 Clinical Trial Results 77 Phase III Clinical Trial 77 Drug Candidate 77 Completes Enrollment 76 Phase III Trial 76 FDA Accepts 75 Preclinical Data 75 Pivotal Phase III 75 RNAi Therapeutics 74 Single Dose 74 Pivotal Trial 73 Presents Positive 73 Metastatic Melanoma 73 Initiate Phase 73 Generic Version 72 Pivotal Study 72 Pivotal Phase 72 II Clinical Trial 71 FDA Clears 71 Pulmonary Arterial Hypertension 71 Cholesterol Drug 71 Prostate Cancer Patients 70 Smallpox Vaccine 70 Announces FDA Clearance 70 Cervical Cancer Vaccine 69 Chronic Hepatitis C 69 FDA Clearance 69 Autoimmune Disease 69 Develop Novel 69 Well Tolerated 69 Initiates Phase 69 Vertex Pharmaceuticals Announces 69 Receives FDA Clearance 69 Patent Covering 69 Small Molecule 69 Positive Opinion 68 Malaria Vaccine 68 Blood Thinner 68 Monoclonal Antibody 68 BioDelivery Sciences 68 Renal Cell Carcinoma 67 Venous Thromboembolism 67 Pluristem Therapeutics 67 Tumor Growth 67 Pediatric Patients 67 Prostate Cancer Treatment 67 Cyclacel Pharmaceuticals 67 Significantly Reduces 67 Significantly Improves 67 Guidance Quick Facts 67 Patient Outcomes 67 Metastatic Colorectal Cancer 66 Low Dose 66 Achieves Milestone 66 Diabetic Patients 66 FY# Guidance 66 Cancer Vaccines 66 Patients Treated 66 Cancer Treatments 66 Monotherapy 66 Metabasis Therapeutics 66 Advanced Prostate Cancer 66 Announces Initiation 66 Study Demonstrates 66 Chronic Hepatitis B 66 Clinical Study 66 Inovio Pharmaceuticals 66 Heart Failure Patients 66 Autoimmune Diseases 66 Combination Therapy 66 Cancer Vaccine 66 Announces Presentation 66 Drug Resistant 66 Postmenopausal Women 65 Updates Guidance 65 Elderly Patients 65 Tesetaxel 65 k Clearance 65 Recombinant Human 65 Influenza Vaccine 65 Inc Therapeutic Competitors 65 Gastric Cancer 65 Breast Cancer Treatment 65 Successful Completion 65 Patients Undergoing 65 Atopic Dermatitis 65 Forecast Quick Facts 65 Annual Meeting Date 65 Newest Version 65 Gene Mutation 65 Myelofibrosis 65 Chronic Lymphocytic Leukemia 65 Receives CE 65 Clinical Trials Update 65 Reduces Risk 65 Q2 Loss Narrows 65 Issues Guidance 65 FDA Approval 65 Aliskiren 65 Overactive Bladder